How to prevent 9 different cancers & genital warts

Are you due for your cervical screening? Learn about the HPV test.


Canada is uniquely positioned to be a major contributor to this important effort. In 2019, a group of experts developed a report with 105 recommendations for implementation of actions both in Canada and internationally to reach the following targets:


  • 90% of girls fully vaccinated with the HPV vaccine by 15 years of age;
  • 90% of women screened with an HPV test; and
  • 90% of women who are identified with cervical disease receive treatment and care.
  • Long-term Study of a Quadrivalent Human Papillomavirus Vaccine. Read Document
  • What is the responsibility of the national government with respect to vaccination? Read Document


  • An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)† 2021-10-21. Read Document
  • THE MISINFORMATION WEB: Learn How to Find and Trust Online Information about HPV Immunization. Read Document
  • HPV vaccination: for women of all ages? Read Document
  • Rebuttal: Do you approve of spending $300 million on HPV Vaccination?- Dr. Marc Steben says yes. Read Document
  • Financial Incentives for Increasing Uptake of HPV Vaccinations: A Randomized Controlled Trial. Read Document,
  • Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. Read Document
  • Valuing Vaccination. Read Document
  • Immunization against HPV in girls with intellectual disabilities. Read Document
  • Early effects of human papillomavirus vaccination in Belgium. Read Document
  • Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer.
  • The age of distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials. Read Document
  • Sex Differences Among College Students in Awareness of the HPV Vaccine and Vaccine Options. Read Document
  • Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programs. Read Document
  • Primary care providers human papillomavirus vaccine recommendations for the medically underserved: A pilot study in U.S. Federally Qualified Health Centers. Read Document
  • Health Canada approves CERVARIX™, new GSK cervical cancer vaccine. Read Document
  • Product Monograph, Cervarix®[Human Papillomavirus vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted)] Suspension for injection, Active Immunizing Agent. ATC code: J07BM02. Read Document
  • Product Monograph, Gardasil® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] Suspension for injection, Active Immunizing Agent. Read Document
  • Part III: Consumer Information, Gardasil® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]. Read Document
  • Product Monograph, Gardasil® 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Suspension for injection, Active Immunizing Agent. Read Document
  • Part III: Consumer Information, Gardasil® 9 [Human Papillomavirus 9-valent Vaccine, Recombinant]. Read Document
  • Beta-Test Results for an HPV Information Website: Increasing HPV Vaccine Uptake in the United States. Read Document
  • Estimation of Geographic Variation in Human Papillomavirus Vaccine Uptake in Men and Women: An Online Survey Using Facebook Recruitment. Read Document


  • Healer of Cancer: The Power of the Mind, by Dr. Christian Boukaram. Read Document
  • The HPV Vaccine Controversy, by Shobha S. Krishnan, M.D. Read Document
  • The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts. Read Document
  • Beliefs, behaviours and HPV vaccine: Correcting the myths and the misinformation. Read Document
  • Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of phase 3, double-blind, randomized controlled VIVIANE study. Read Document
  • The Politics of HPV Vaccination Advocacy: Effects of Source Expertise on Effectiveness of a Pro-Vaccine Message. Read Document
  • Human Papillomavirus Vaccine Knowledge and Attitudes, Preventative Health Behaviours, and Medical Mistrust Among a Racially and Ethnically Diverse Sample of College Women. Read Document
  • Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescent and young adults. Read Document


  • Are twenty human papillomavirus types causing cervical cancer? Read Document
  • Human Papillomavirus and Related Diseases in Canada. Summary Report 2015-03-20. Read Document
  • Implementation Science in Cancer Prevention and Control: A framework for research and programs in low and middle-income countries. Read Document
  • Otolaryngology-Head and Neck Surgery. Read Document


  • Including males in Canadian human papillomavirus vaccination programs: a policy analysis. Read Document
  • Indications for the HPV vaccine in adolescents: A review of the literature. Read Document
  • Missed Opportunities for HPV Vaccination in Adolescent Girls: A Qualitative Study. Read Document
  • Adverse events following immunization in Ontario’s female school-based HPV program. Read Document
  • Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study. Read Document


  • Sex Is Like Jelly Beans: Educating Students on the Risks of Oral Sex. Read Document
  • A risk for non-sexual transmission of human papillomavirus? Read Document